Strategic partnerships Lodo Therapeutics has previously engaged in collaborations and acquisitions with notable players (Zymergen, ALSP, BioSpace collaborations), indicating a readiness to partner with industry leaders. This suggests sales opportunities through co-development, licensing, or exclusive collaboration deals to advance their oncology-focused internal pipeline.

Early-stage to scale With a recent Series A of 17M and a small team (2-10 employees), Lodo is in growth mode but remains lean. Sales opportunities exist in scalable platforms and services that can support rapid amplification of their discovery capabilities, such as high-throughput screening, data analytics, and synthetic biology tooling.

AI and tech leverage Lodo emphasizes next-generation sequencing, AI/ML, and synthetic biology to accelerate natural product discovery. This creates demand for advanced computational infrastructure, data management solutions, and cloud-based AI services, as well as potential partnerships with analytics and software providers.

Undruggable targets Focusing on undruggable targets with environmental microbial DNA positions Lodo to target niche, high-value therapeutic areas. There are sales opportunities in platform licensing, target discovery services, and customized screening campaigns tailored to difficult targets.

Global partnering Their expansion into partnering across indications beyond oncology and experience with global collaborators indicate appetite for structured alliances, co-development, and milestone-driven deals. Target potential buyers or partners seeking access to diverse natural product libraries and discovery platforms.